Professor Richard Price
Contact information
Podcast interview
Curing Plasmodium vivax malaria
Vivax malaria used to be considered benign but is now recognised as an important cause of morbidity and mortality. Resistance to chloroquine (given to treat the parasite blood stage) is growing and ACT (artemisinin-based combination therapy) is becoming common treatment for vivax malaria. New drugs and better public health strategies can help elimination targets, anticipated for 2030.
Research groups
Ethiopian Clinic
Vietnam Hospital
Richard Price
Professor of Tropical Medicine
Vivax malaria
The main focus of our translational research programme is to improve the diagnosis and management of vivax malaria. To achieve this we are working with in malaria endemic countries across the Asia-Pacific region and Horn of Africa to:
- optimise the safe and effective radical cure of vivax malaria,
- improve the molecular surveillance of drug resistant malaria
- define the morbidity and mortality of vivax malaria
- evaluate the impact and cost effectiveness of novel treatment and malaria control activities.
The programme is being conducted in collaboration with the Mahidol Oxford Research Unit (MORU) in Thailand and the Menzies School of Health Research (MSHR) in Darwin.
I am head of the clinical module of the World Wide Antimalarial Resistance Network (WWARN). Between 2010-2020 he established co-chair the Vivax Working Group of the Asia-Pacific Malaria Elimination Network (APMEN).
CURRENT PROJECTS:
- Clinical trials and implementation studies of different primaquine regimens
- Field testing novel G6PD diagnostics
- Mapping populations at risk of malaria and drug induced haemolysis
- Determining the molecular basis of chloroquine resistant P. vivax
- Individual patient data metanalyses of antimalarial efficacy studies
Timika, Papua, Indonesia
RSMM Hospital
Sumatra Site for IMPROV Study
Ex vivo Lab
Recent publications
-
Enhanced data quality to improve malaria surveillance in Papua, Indonesia
Fransisca L. et al, (2025), Malaria Journal, 24
-
Acceptability and feasibility of glucose-6-phosphate dehydrogenase (G6PD) testing using SD Biosensor by village malaria workers in Cambodia: a qualitative study.
Cassidy-Seyoum SA. et al, (2025), BMJ global health, 10
-
Co-design of a routine clinical review to improve the safety of high dose radical cure treatment for Plasmodium vivax malaria: findings from Cambodia and Ethiopia
Cassidy-Seyoum SA. et al, (2025), Malaria Journal, 24
-
Malaria morbidity, mortality and associated costs in Indonesia: analysis of the National Health Insurance claim dataset.
Setiawan E. et al, (2025), BMJ Glob Health, 10
-
FocaL mass drug Administration for Plasmodium vivax Malaria Elimination (FLAME): study protocol for an open-label cluster randomized controlled trial in Peru.
Fine S. et al, (2025), Res Sq
-
Safety and efficacy of single-dose primaquine to interrupt Plasmodium falciparum malaria transmission in children compared with adults: a systematic review and individual patient data meta-analysis.
Yilma D. et al, (2025), The Lancet. Infectious diseases